Australia markets closed

Celyad Oncology SA (CLYYF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
9.150.00 (0.00%)
At close: 5:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.15
Open9.15
BidN/A x N/A
AskN/A x N/A
Day's range9.15 - 9.15
52-week range9.15 - 12.24
Volume1,500
Avg. volume0
Market cap60.555M
Beta (5Y monthly)1.48
PE ratio (TTM)N/A
EPS (TTM)-1.52
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
    Business Wire

    Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

    MONT-SAINT-GUIBERT, Belgium, Jun 11, 2021--Regultory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced preliminary data from the Phase 1 IMMUNICY-1 trial of CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) patients were presented at the European Hematology Associati

  • Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
    GlobeNewswire

    Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

    MONT-SAINT-GUIBERT, Belgium, May 31, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on May 31, 2021 a capital increase of 182,000 new shares of the Company through its Open Market Sale AgreementSM with Jefferies LLC. As a result, the Company’s share capital is increased to 52,844,560.33 EUR and is represented by 15,187,156 shares. This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.Figures – Modified on 31 May 2021 following the Capital Increase: Total amount of share capital (EUR)52,844,560.33Total Number of shares with single voting rights12,819,131Total Number of shares with double voting rights2,368,025Total Number of Shares15,187,156Total of voting rights17,555,181Total number of attributed warrants1,927,756Total number of shares with voting rights that could be created following the exercise of the attributed warrants1,927,756Total number of diluted shares (Outstanding shares + Warrants)17,114,912Total number of diluted shares with voting rights19,482,937 Contact person for regulated information (financial, transparency) By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com. Further questions about the content of this release can be sent to investors@celyad.com. About Celyad Oncology Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Forward-Looking Statement This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial results in the first half of 2021, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, our financial and operating results and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 24, 2021 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. Investor and Media Contacts: Sara ZelkovicCommunications & Investor Relations DirectorCelyad Oncology investors@celyad.com Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com Source: Celyad Oncology SA

  • Celyad Oncology Announces June 2021 Conference Schedule
    GlobeNewswire

    Celyad Oncology Announces June 2021 Conference Schedule

    MONT-SAINT-GUIBERT, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in June 2021: Jefferies Virtual Healthcare Conference Dates: Tuesday, June 1 – Friday June 4, 2021Presentation date: Tuesday, June 1, 2021Time: 11:00 a.m. EST / 5:00 p.m. CETPresenter: Filippo Petti, CEOWebcast: A webcast of the presentation will be available in the Events section of the Celyad Oncology website. William Blair & Company Annual Growth Stock ConferenceDates: Tuesday, June 1 – Thursday, June 3, 2021Presentation date: Wednesday, June 2, 2021 Time: 11:00 a.m. EST / 5:00 p.m. CETPresenter: Filippo Petti, CEOWebcast: An archived webcast of the presentation will be available in the Events section of the Celyad Oncology website JMP Securities Life Sciences ConferenceDates: Wednesday, June 16 – Thursday, June 17, 2021Presentation date: Thursday, June 17, 2021Time: 11:30 a.m. EST / 5:30 p.m. CETPresenter: Filippo Petti, CEO Kepler Cheuvreux Digital Life Science DayDate: June 22, 2021 About Celyad Oncology SA Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Forward-Looking Statement This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. Investor and Media Contacts: Sara ZelkovicDaniel FerryCommunications & Investor Relations DirectorManaging DirectorCelyad OncologyLifeSci Advisors, LLCinvestors@celyad.com daniel@lifesciadvisors.com Source: Celyad Oncology SA